Lignans MarketSize, Share & Industry Analysis, 2026-2034By SourceBy ApplicationBy TypeBy FormBy Distribution Channel

Lignans are naturally occurring plant phenolic compounds, most commonly extracted from flaxseed, cereal brans and specialty plant resins, valued for their antioxidant and phytoestrogen properties. They are supplied as powders, liquid extracts, or granulated and encapsulated forms for use as functional ingredients. Buyers include food and beverage manufacturers, dietary supplement and nutraceutical companies, cosmetics and personal care formulators, pharmaceutical companies and animal feed producers, each incorporating lignans into finished products for antioxidant, hormonal-balance or nutritional positioning.

Between 2025 and 2034 the global lignans market moves from USD 505 million to USD 912.5 million, compounding at 6.79% a year. Fifteen years are covered in all, taking in USD 386.4 million in 2020, USD 478.5 million in 2024, USD 539.4 million in 2026 and USD 701.4 million in 2030.

On the source axis, growth rates run from 5.63% for Cereals & Grains up to 11.1% for Plant Resins. Oilseeds carries the volume: USD 292.2 million and 57.9% of revenue in 2025, USD 492.8 million and 54% in 2034. Share moves toward Plant Resins and away from Oilseeds and Cereals & Grains, though no line shrinks in revenue terms.

Cut by application, the largest line is Dietary Supplements: 24% of 2025 revenue, worth USD 121.2 million, and 27% at USD 246.4 million by 2034. Skincare grows faster at 10.4% against 9.28%, moving from 9% of revenue to 11% by 2034. Both this axis and the source one divide the same revenue, which is why they are alternative views, not components.

USD 168.8 million of 2025 revenue is generated in Asia Pacific, 33.4% of the global total and the largest regional share; it reaches USD 328.5 million by 2034. North America is next at 26.9% and USD 136 million, and Middle East and Africa last at 6.5%. Share shifts toward Asia Pacific and Latin America over the forecast period, so the regional split repays a close reading.

Behind these figures sit five regions, three source lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is a triangulation of published figures and category proxies, short of a directly sourced total, and the same applies to the segment, regional and country breakdowns drawn from it.

• Revenue grows from USD 505 million in 2025 to USD 912.5 million in 2034, a compound annual rate of 6.79%, having reached USD 478.5 million in 2024 from USD 386.4 million in 2020.
• Oilseeds is the largest source line at USD 292.2 million in 2025, a 57.9% share, reaching USD 492.8 million and 54% of revenue by 2034.
• Fastest growth on the source axis belongs to Plant Resins: 11.1% a year, USD 73.6 million to USD 191.6 million, and a share moving from 14.6% to 21%.
• The bull case puts 2034 revenue at USD 1003.8 million and the bear case at USD 821.3 million, either side of the USD 912.5 million base case, each with its own stated assumption in the full report.
• The largest region is Asia Pacific, generating USD 168.8 million in 2025 (33.4% of the global total) and USD 328.5 million by 2034, ahead of North America at 26.9%.
• Within Asia Pacific, China is the worked country example, at USD 76 million in 2025; 45% of regional revenue in the base year, and USD 147.8 million by 2034.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Read across the forecast period, the global lignans market shows movement in three places: source composition, regional weight, and the 6.79% rate applied to the whole.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.

Composition shifts on the source axis. 11.1% against 5.63%: that gap, between Plant Resins and Cereals & Grains, is the largest on the source axis. Over the forecast period that moves Plant Resins from 14.6% of revenue to 21%, and Cereals & Grains from 27.6% to 25%. Revenue rises on both sides; USD 73.6 million to USD 191.6 million and USD 139.2 million to USD 228.1 million respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

Asia Pacific and Latin America gain regional share. Asia Pacific moves from 33.4% of revenue in 2025 to 36% in 2034, worth USD 168.8 million rising to USD 328.5 million; Latin America moves from 8.9% of revenue in 2025 to 9.5% in 2034, worth USD 44.7 million rising to USD 86.7 million. Share moves off the others in turn: North America at 26.9% moving to 25%, Europe at 24.3% moving to 23%, Middle East and Africa at 6.5% moving to 6.5%, each still growing in revenue terms. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

The series never breaks trajectory. Year by year the total runs USD 386.4 million in 2020, USD 478.5 million in 2024, USD 505 million in 2025, USD 539.4 million in 2026, USD 701.4 million in 2030 and USD 912.5 million in 2034. No year breaks the trajectory, and the 6.79% forecast rate compares with 5.5% recorded over 2020-2025, a continuation, not an inflection. The risk in the number sits in the mix assumptions, not in whether the market grows at all, which is where the source and regional sections come in.

Growth is concentrated in Plant Resins

Separate the 6.79% into its parts and three show up: an already-large base compounding, the source mix moving toward its faster lines, and regional growth landing unevenly.

The bear case and what drives it

Where the forecast could be beaten

Revenue is concentrated in Oilseeds

In North America, 26.9% of global revenue puts 2025 at USD 136 million on the way to USD 228.1 million by 2034. Among the five regions it ranks second by revenue in both years.

Its share moves to 25% by 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Within the region the source split tracks the global one; 57.9% of 2025 revenue in Oilseeds, fastest growth of 11.1% in Plant Resins. Per-axis and per-country detail for North America sits in the full report.

85% of North America's base-year revenue comes from the United States; USD 115.6 million, rising to USD 193.9 million by 2034. At 85% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. The region itself runs USD 136 million to USD 228.1 million over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Oilseeds at 57.9% of 2025 revenue, easing to 54% by 2034, and the fastest is Plant Resins at 11.1%, from 14.6% to 21%. Because the country carries 85% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-source revenue for the United States appears on its own in the full report.

Lignans intended for use in dietary supplements or as an added ingredient in conventional foods fall under the Food and Drug Administration's framework for dietary ingredients and food additives. A supplier marketing a lignan extract as a dietary supplement must ensure the ingredient qualifies under the Dietary Supplement Health and Education Act, either as an ingredient marketed before the relevant cutoff date or through a New Dietary Ingredient notification demonstrating a reasonable expectation of safety. Structure-function claims are permitted on labels only with a standard disclaimer, and no claim may state that the product diagnoses, treats, cures or prevents disease. Where lignans are added to conventional food, the supplier must confirm the ingredient is Generally Recognized As Safe or has undergone the appropriate food additive review. Labelling must comply with the FDA's nutrition and supplement facts panel requirements, including accurate identification of the source material.

The suppliers tracked in this study (Kingherbs, Naturalin Bio-Resources Co. Ltd., BioGin Biochemicals Co. Ltd., TSKG Products LLC, Shaanxi Zebrago Industrial Co. Ltd., Prairie Tide Diversified Inc., SPI Pharma, Skuny Bioscience, Plamed, Neimenggu Wonderful, Hunan NutraMax, Hebei Xinqidian Biotechnology and Hangzhou Excelente) compete in the United States across the source lines above. Volume sits in Oilseeds at 57.9% of 2025 revenue; movement sits in Plant Resins at 11.1% growth. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.

Canada is sized at USD 20.4 million in 2025, rising to USD 34.2 million by 2034; 4% of global revenue and 15% of North America. It is reported separately from the United States across every segmentation axis in the full report.

24.3% of the global lignans market sits in Europe in 2025, worth USD 122.7 million with USD 209.9 million projected for 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

Its share moves to 23% by 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the source split tracks the global one; 57.9% of 2025 revenue in Oilseeds, fastest growth of 11.1% in Plant Resins. Europe is reported axis by axis and country by country in the full study.

USD 36.8 million of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 63 million by 2034. It accounts for 30% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 122.7 million and USD 209.9 million for the region, it is why this market, and not a smaller one, is the one reported in full.

Demand in Germany follows the source mix reported at global level: Oilseeds is the largest line at 57.9% of 2025 revenue, moving to 54% by 2034, while Plant Resins grows fastest at 11.1% and takes its share from 14.6% to 21%. Since 30% of Europe's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Revenue by source for Germany is reported separately in the full report.

As an EU member state, Germany applies the Novel Food Regulation to lignan preparations that lack a documented history of consumption before the relevant reference period; a supplier introducing such an ingredient must secure authorisation through the European Food Safety Authority's novel food assessment before it can be marketed. Lignans used in food supplements are additionally governed by the EU Food Supplements Directive as implemented in German national law, which sets requirements for composition, purity and labelling. Health claims referencing lignans must be substantiated and pre-approved under the EU Nutrition and Health Claims Regulation, and unauthorised claims cannot appear on packaging. The Bundesinstitut für Risikobewertung advises on safety assessments feeding into these decisions. Labels sold in Germany must be presented in German and disclose the botanical source, recommended intake and any relevant allergen information.

Kingherbs, Naturalin Bio-Resources Co. Ltd., BioGin Biochemicals Co. Ltd., TSKG Products LLC, Shaanxi Zebrago Industrial Co. Ltd., Prairie Tide Diversified Inc., SPI Pharma, Skuny Bioscience, Plamed, Neimenggu Wonderful, Hunan NutraMax, Hebei Xinqidian Biotechnology and Hangzhou Excelente are the suppliers covered in Germany. Two different problems sit on the same axis: holding Oilseeds at 57.9% of 2025 revenue, and taking Plant Resins while it grows at 11.1%. Weighting toward Europe means competing for 24.3% of 2025 global revenue, a base of USD 122.7 million moving to USD 209.9 million across the forecast period.

France is sized at USD 24.5 million in 2025, rising to USD 42 million by 2034; 4.9% of global revenue and 20% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

In Asia Pacific, 33.4% of global revenue puts 2025 at USD 168.8 million rising to USD 328.5 million in 2034. That makes it the first-largest region covered, in 2025 and again in 2034.

36% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 6.79%; the revenue added here is disproportionate to where the region started.

Within the region the source split tracks the global one; 57.9% of 2025 revenue in Oilseeds, fastest growth of 11.1% in Plant Resins. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

45% of Asia Pacific's base-year revenue comes from China; USD 76 million, rising to USD 147.8 million by 2034. It accounts for 45% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 168.8 million in 2025 and USD 328.5 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

China buys along the same lines as the market globally; Oilseeds first at 57.9% of 2025 revenue and 54% in 2034, Plant Resins fastest at 11.1% on a share moving from 14.6% to 21%. Because the country carries 45% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports China by source separately.

Lignans marketed in China as a health food ingredient fall under the oversight of the State Administration for Market Regulation, which administers both the registration and filing pathways for health foods depending on the ingredient's novelty and claimed function. A supplier introducing a lignan-based product must determine whether it qualifies for the simplified filing route or requires full registration, which involves safety and functional evaluation. If the lignan source itself has no established history of use in China, it may additionally need clearance as a novel food ingredient through the National Health Commission. Labelling must follow the national standards for health food, disclosing ingredient composition, recommended consumption and cautionary statements, and any functional claim must correspond to an approved category rather than an open-ended health assertion.

In China the field is Kingherbs, Naturalin Bio-Resources Co. Ltd., BioGin Biochemicals Co. Ltd., TSKG Products LLC, Shaanxi Zebrago Industrial Co. Ltd., Prairie Tide Diversified Inc., SPI Pharma, Skuny Bioscience, Plamed, Neimenggu Wonderful, Hunan NutraMax, Hebei Xinqidian Biotechnology and Hangzhou Excelente. The commercially relevant division is 57.9% of 2025 revenue in Oilseeds, where the volume is, against 11.1% growth in Plant Resins, where share moves. The commercial size of that position is USD 168.8 million in 2025 and USD 328.5 million by 2034, 33.4% of the global total in the base year.

India is sized at USD 33.8 million in 2025, rising to USD 65.7 million by 2034; 6.7% of global revenue and 20% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

In Latin America, 8.9% of global revenue puts 2025 at USD 44.7 million on the way to USD 86.7 million by 2034. Among the five regions it ranks fourth by revenue in both years.

By 2034 the share has moved up to 9.5%, on growth above the market's own 6.79%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

The source mix reported at global level applies here, with Oilseeds the largest line at 57.9% of 2025 revenue and Plant Resins the fastest-growing at 11.1%. Latin America is reported axis by axis and country by country in the full study.

USD 22.4 million of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 43.4 million by 2034. It accounts for 50% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 44.7 million in 2025 and USD 86.7 million in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is Oilseeds at 57.9% of 2025 revenue, easing to 54% by 2034, and the fastest is Plant Resins at 11.1%, from 14.6% to 21%. Since 50% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Brazil carries its own source breakdown in the full report.

In Brazil, lignan ingredients used in foods or supplements are regulated by the Agência Nacional de Vigilância Sanitária, which classifies such substances under its framework for new foods and new ingredients when no established pattern of consumption exists in the country. A supplier must submit technical and safety documentation supporting the proposed use level before the ingredient can be marketed, and any functional or health claim requires separate substantiation consistent with Anvisa's rules on nutrition and health claims. Products must comply with Anvisa's general labelling requirements for foods and supplements, including clear identification of the ingredient, its botanical origin where applicable, and directions for use. Conformity with Brazilian technical standards for supplement composition and contaminant limits is also required before a product reaches the market.

Kingherbs, Naturalin Bio-Resources Co. Ltd., BioGin Biochemicals Co. Ltd., TSKG Products LLC, Shaanxi Zebrago Industrial Co. Ltd., Prairie Tide Diversified Inc., SPI Pharma, Skuny Bioscience, Plamed, Neimenggu Wonderful, Hunan NutraMax, Hebei Xinqidian Biotechnology and Hangzhou Excelente are the suppliers covered in Brazil. Two different problems sit on the same axis: holding Oilseeds at 57.9% of 2025 revenue, and taking Plant Resins while it grows at 11.1%. That makes Latin America a 8.9% share of 2025 global revenue, USD 44.7 million rising to USD 86.7 million, for any supplier deciding where to concentrate.

Within Latin America, Argentina accounts for 30% of regional revenue and 2.7% of the global total, worth USD 13.4 million in 2025 and USD 26 million by 2034.

Middle East and Africa holds 6.5% of the global lignans market in 2025, worth USD 32.8 million on the way to USD 59.3 million by 2034. Among the five regions it ranks fifth by revenue in both years.

By 2034 the share stands at 6.5%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

The source mix reported at global level applies here, with Oilseeds the largest line at 57.9% of 2025 revenue and Plant Resins the fastest-growing at 11.1%. The full report breaks Middle East and Africa out along every axis and by country.

The largest single market in Middle East and Africa is South Africa, at USD 13.1 million in 2025 and USD 23.7 million in 2034. At 40% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Set against USD 32.8 million and USD 59.3 million for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Oilseeds at 57.9% of 2025 revenue, easing to 54% by 2034, and the fastest is Plant Resins at 11.1%, from 14.6% to 21%. Its 40% weight in Middle East and Africa means those movements carry straight into the regional totals. The full report reports South Africa by source separately.

South Africa regulates lignan-containing foods and supplements through the Department of Health under the Foodstuffs, Cosmetics and Disinfectants Act, with the South African Health Products Regulatory Authority overseeing complementary medicines and health supplements where a lignan product is positioned in that category. A supplier must classify the product correctly at the outset, since a supplement-type claim shifts the ingredient into a more detailed registration and safety-evidence pathway than a plain foodstuff would require. Labelling must meet the national regulations governing labelling and advertising of foodstuffs, disclosing composition and any permitted health claim in line with the approved list. Where a lignan ingredient has no prior history of use in the domestic market, the supplier may also need to demonstrate its safety to the relevant authority before distribution proceeds.

Competition in South Africa runs between the suppliers this study tracks: Kingherbs, Naturalin Bio-Resources Co. Ltd., BioGin Biochemicals Co. Ltd., TSKG Products LLC, Shaanxi Zebrago Industrial Co. Ltd., Prairie Tide Diversified Inc., SPI Pharma, Skuny Bioscience, Plamed, Neimenggu Wonderful, Hunan NutraMax, Hebei Xinqidian Biotechnology and Hangzhou Excelente. Two different problems sit on the same axis: holding Oilseeds at 57.9% of 2025 revenue, and taking Plant Resins while it grows at 11.1%. A supplier weighted toward Middle East and Africa is competing over a base of USD 32.8 million in 2025 reaching USD 59.3 million by 2034, 6.5% of global revenue at the start of that period.

1.6% of global revenue is generated in UAE; USD 8.2 million in 2025, reaching USD 14.8 million in 2034, and 25% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by source, application, type, form, distribution channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.